Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Kamada AAT

Plasma-derived product · developed by Kamada

Phase 2/3 Most advanced trial (none active)
KMDA Developer
2 Registered trials

What is Kamada AAT?

Kamada AAT is an inhaled formulation of alpha-1 antitrypsin, the protein that is deficient in alpha-1 antitrypsin deficiency. It is being studied for emphysema and alpha-1 antitrypsin deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Plasma-derived product
Therapy area
Respiratory
Developer
Kamada, Ltd. (KMDA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01217671 Phase 2/3 Emphysema Completed KMDA
NCT02001688 Phase 2 Alpha-1 Antitrypsin Deficiency Completed KMDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alpha-1 Antitrypsin DeficiencyEmphysema

More from Kamada

Follow KMDA, the company behind Kamada AAT

See KMDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KMDA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.